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care environment, and data analytics. CONCLUSIONS: The integration of pharma-
cogenomic testingwith real-world studies offers an important opportunity to iden-
tify sub-groups of patients for whom treatment is more effective in terms of clin-
ical, and safety outcomes. Alongside resource utilization and cost of care data, this
evidence can be used to populate cost-effectiveness and other health economic
analyses to inform physician and payer decision-making.
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OBJECTIVES: Retrospective database studies commonly use an inclusion criterion
requiring that subjects have a minimum duration of post-index enrollment (i.e.,
follow-up). Such a criterion can simplify analysis and facilitate computation of
annual costs. In clinical trials, however, similar strategies, such as analyses re-
stricted to subjects who completed follow-up (“complete case analysis”), are seen
as problematic because reasons for discontinuation may be related to study end-
points (i.e., informative censoring). METHODS: We reviewed methodologic litera-
ture and we used a health insurance claims database to evaluate the impact on
health care utilization and costs of excluding subjects lost to follow-up. RESULTS:
Excluding from analysis subjects with incomplete follow-up may be valid if pa-
tients aremissing at random. Unfortunately, this assumption can rarely be verified
because endpoints are usually unknown for patients who are lost to follow-up. In
an insurance claims database, an inclusion criterion requiring one year of fol-
low-up decreased health care utilization and average annual costs by 8% for a
random sample of subjects, and by 17% among subjects with a serious illness.
CONCLUSIONS: Subjects are lost to follow-up in both clinical trials and retrospec-
tive database studies (e.g., by exiting the database). Study populations should not
be defined in such a way as to exclude subjects lost to follow-up; instead, subjects
lost to follow-up should be considered as a missing data problem. In retrospective
database studies, just as in clinical trials, if endpoints among subjects lost to fol-
low-up differ from endpoints among subjects remaining in the database, restrict-
ing analysis to patientswithminimumdurations of follow-up candistort outcomes
and economic evaluations. Subjects lost to follow-up in automated databases
should be described and evaluated for evidence of informative censoring, and an-
alyzed using strategies appropriate for missing data, such as multiple imputation
methods.
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OBJECTIVES: To evaluate the potential for duplicate counting of prescriptionmed-
ication utilization for products that are billed through medical and prescription
claims. METHODS: A retrospective cross-sectional descriptive study was con-
ducted using the 2008 – 2011 Mississippi Medicaid data. Medical claims (MCs) with
J-codes for injectable medications were identified from MC files. Prescription
claims (PCs) for the corresponding beneficiaries were extracted from PC data for all
NDCs associated with the J-codes identified. These two sets of claims were stacked
to obtain a denominator file. Potential duplicate counts were identified by pairing
MCs and PCs for the same beneficiary and drug where the PC service date was
within 7 days of the MC service date. The Medicare maximum allowable cost was
identified for the J-code in each potential duplicate count situation. Criteria of the
MC being 80%of themaximumallowable cost for one J-code unit and theMC paid
amount being 80% of the corresponding PC paid amount were used to evaluate
which pairs might be actual duplicate counts. RESULTS: Out of 1,813,251 claims
identified in the denominator file, 1443 drug eventswere considered to be potential
duplicate counts (0.08%). These claims were associated with 849 Medicaid enroll-
ees. For 89%of the pairs, theMCpaid amountwas 80%of the allowable J-code unit
cost and 37% were 80% of the corresponding PC paid amount. Using a combina-
tion of these criteria, it was estimated that at least 47% of the pairs were likely to be
duplicate counts and that a large portion of the other pairs might be duplicate
counts. CONCLUSIONS: Researchers need to use caution when counting medica-
tion events for products reimbursed as MCs and PCs. The error from over-counting
at the population level should be small, but could have significant impact on utili-
zation and adherence estimates for individual patients.
PRM7
A REVIEW AND APPLIED COMPARISON OF META-ANALYSIS TECHNIQUES
Lewis-Beck C1, Baser E2, Baser O3
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Istanbul, Turkey,
3STATinMED Research/The University of Michigan, Ann Arbor, MI, USA
BACKGROUND: Numerous assumptions and techniques are associated with per-
forming meta-analysis. While some overall structural guidelines and recom-
mended practices exist, there are very few papers that compare meta-analysis
techniques in application.OBJECTIVES: To review primarymeta-analysismethods
and their assumptions, and apply various meta techniques to data and compare
the results. METHODS: There are currently a myriad of meta-analysis techniques
available. We started the study with a review of fixed effects models, which is the
most basic technique that assumes homogeneity in treatment effect across stud-
ies. We then explored random effect models and meta regression. Each of these
techniques models treatment heterogeneity. Other more advanced techniques ex-
amined included mixed treatment comparisons (MTC) and Bayesian approaches.
RESULTS: Estimates of treatment effect differed depending on themeta technique
applied. When a fixed effect model was applied to estimate the effect of a vaccina-
tion against tuberculosis, the log odds ratio was -0.436 (confidence interval [CI:
-0.528, -0.344]). After testing for heterogeneity and fitting a random effects model,
the estimate was reduced to -0.741 (CI [-1.12, -0.352]), and the CI became wider.
When covariates were added to the model to explain the heterogeneity, the treat-
ment effect was reduced even further. Additional techniques were applied as well,
such as BayesianMTC. CONCLUSIONS: Results frommeta-analysis are sensitive to
the studies selected, in addition to themethodology applied. To ensure that proper
techniques are used, it is critical to estimate an unbiased outcome.
RESEARCH ON METHODS – COST METHODS
PRM8
GENERAL TRANSFERABILITY OF MODEL-BASED ECONOMIC EVALUATIONS
Carswell C, McWilliams P, Williamson KA, Faulds D
Adis, Auckland, New Zealand
OBJECTIVES: Economic evaluations of drug therapy are important, but time con-
suming and costly. Analyses that are easily transferable (i.e. adjustable to a differ-
ent jurisdiction without completely rebuilding the model) may potentially save
time and resources. We aimed to develop a tool to assess and summarize the
general transferability ofmodel-based analyses.METHODS:Medline was searched
for literature on transferability published between 2002 and June 2011. Existing
checklists for economic evaluations were adapted to create a checklist of 16 key
factors to assess the general transferability of model-based analyses. This tool was
used to score 11 recently published economic evaluations and identify how well
specific factors were addressed. RESULTS: Transferability scores of the selected
papers ranged from 53–91%, illustrating the wide variability in the quality of re-
porting. Across all studies, the least well addressed transferability factors included
the discussion of the generalizability of the study results (lacking or incomplete in
all studies), adequate description of resources and costs employed in the analysis
(particularly separate reporting of resource use and unit costs), and adequate de-
scriptions of the method and/or populations used to derive utility values. The best
addressed transferability factors included those relating to country, currency and
discount rates. Even if studies scored highly overall, it may still be difficult to
transfer the findings to a different setting if they failed to report insufficient detail
on one or two key parameters. CONCLUSIONS: The general transferability of a
model-based economic evaluation from one country or jurisdiction to another can
be quickly assessed by the application of a simple checklist of key transferability
factors. It is important that authors ensure that they report their economic analysis
in a detailed and transparent fashion.
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OBJECTIVES: To perform a systematic literature review of pharmacoeconomic (PE)
publications considering recent United States (US) Food and Drug Administration
(FDA) new molecular entity and new biologic license approvals (NMEs/NBLs). The
review investigated publication quality and US relevance. METHODS: MEDLINE
and the United Kingdom National Health Service Economic Evaluation Database
were searched. Included publications considered 2008-2009 NMEs/NBLs in original
PE evaluations. In addition to general characteristics, each publication was evalu-
ated using the Quality of Health Economic Studies (QHES) Instrument. The corre-
lation between QHES scores and the 2010 Thomson Reuters five-year journal Im-
pact Factor (IF-5y) was calculated. Median QHES score differences were compared
(Mann-Whitney U) by study characteristics (yes/no): US context, academic first
author, pharmaceutical manufacturer funding (PMF), and declared author
independence. RESULTS: From 115 unique search results, 31met inclusion criteria.
Of fifty 2008-2009 NMEs/NBLs, 36% had PE publications, with 81% considering the
approval indication and 61% published post-approval. A US context was assessed
in 35% of publications. PMF was present in 68% of publications, comprising man-
ufacturers marketing either the NME/NBL, 90%, or a comparator, 10%. Time
(meanstandard deviation (S.D.)) since FDA approval was 21.98.8 months until
ePublication and 15.39.0 months until journal submission. Median and
meanS.D. QHES score were 78 and 73.316.4, respectively. Publications most
often satisfied QHES items regarding uncertainty (5) and incremental analysis (6)
(94% each). Justifiying the chosen model (13) and discussing biases (14) were satis-
fied least often (38% each). The IF-5y (mean 3.46, S.D. 3.37) was not correlated
with QHES score (Pearson r0.095, p0.636). QHES scores were not-significantly
different (p0.05) for any study characteristics. CONCLUSIONS: QHES scores indi-
cate PE studies of recent NMEs/NBLs are high quality, although US relevance is
imperfect: few publications assessed a US context; some did not consider the ap-
proval indication; publication lags delay PE evidence availability; and most publi-
cations have PMF.
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OBJECTIVES: To study whether theminimally important differences (MIDs) values
outcomes based on the behavioral economic theory. METHODS: We studied the
behavior of individuals discriminating minimally important differences (MIDs), a
method that identifies the change in a health measure necessary for a patient to
discriminate an improvement. The behavioral theory predicts that discrimination
of a quantity is governed byWeber’s Law: If a quantity is increased by some factor,
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